Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Charles River Laboratories Intl (CRL)

Charles River Laboratories Intl (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,248,644
  • Shares Outstanding, K 49,228
  • Annual Sales, $ 4,015 M
  • Annual Income, $ -144,340 K
  • EBIT $ 580 M
  • EBITDA $ 1,149 M
  • 60-Month Beta 1.63
  • Price/Sales 2.04
  • Price/Cash Flow 7.57
  • Price/Book 2.58

Options Overview Details

View History
  • Implied Volatility 42.55% (-3.57%)
  • Historical Volatility 52.55%
  • IV Percentile 43%
  • IV Rank 19.10%
  • IV High 86.39% on 04/11/25
  • IV Low 32.21% on 06/18/25
  • Expected Move (DTE 21) 13.56 (7.73%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 846
  • Volume Avg (30-Day) 1,783
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 14,708
  • Open Int (30-Day) 9,544
  • Expected Range 161.90 to 189.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 2.05
  • Number of Estimates 8
  • High Estimate 2.43
  • Low Estimate 1.91
  • Prior Year 2.34
  • Growth Rate Est. (year over year) -12.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
146.33 +19.91%
on 02/18/26
224.77 -21.94%
on 01/27/26
-46.89 (-21.09%)
since 01/26/26
3-Month
146.33 +19.91%
on 02/18/26
228.88 -23.34%
on 01/13/26
-3.48 (-1.94%)
since 11/26/25
52-Week
91.86 +91.01%
on 04/11/25
228.88 -23.34%
on 01/13/26
+7.50 (+4.47%)
since 02/26/25

Most Recent Stories

More News
Charles River Laboratories Provides Update on Planned Divestitures

– Announces Signing of Definitive Agreements to Divest the CDMO and Cell Solutions Businesses and Certain European Discovery Services Assets – – Updates 2026 Financial...

CRL : 175.46 (+4.71%)
Integra LifeSciences, Enovis, BrightSpring Health Services, IQVIA, and Charles River Laboratories Shares Plummet, What You Need To Know

Integra LifeSciences, Enovis, BrightSpring Health Services, IQVIA, and Charles River Laboratories Shares Plummet, What You Need To Know

ENOV : 25.42 (+13.89%)
IART : 11.33 (-2.24%)
BTSG : 40.13 (-1.64%)
CRL : 175.46 (+4.71%)
IQV : 170.64 (+5.39%)
What Are Wall Street Analysts' Target Price for Charles River Laboratories Stock?

Charles River Laboratories has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

XLV : 157.42 (-0.26%)
$SPX : 6,908.86 (-0.54%)
CRL : 175.46 (+4.71%)
CRL Q4 Deep Dive: Flat Sales and Margin Pressures as Biotech Demand Recovers

CRL Q4 Deep Dive: Flat Sales and Margin Pressures as Biotech Demand Recovers

CRL : 175.46 (+4.71%)
Stocks Rally on Signs of US Economic Resilience

The S&P 500 Index ($SPX ) (SPY ) today is up +0.84%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.63%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.20%. March E-mini S&P futures (ESH26...

AMAT : 375.72 (-4.87%)
B : 50.35 (+1.08%)
KNF : 89.38 (+0.90%)
HL : 24.54 (+5.28%)
GPN : 77.85 (-0.12%)
CDE : 26.56 (+8.01%)
ADI : 354.35 (-1.79%)
GLBE : 35.96 (+2.48%)
$IUXX : 25,034.37 (-1.16%)
ASML : 1,463.80 (-4.11%)
ZNM26 : 113-180 (+0.18%)
ESH26 : 6,903.00 (-0.25%)
Stocks Climb on Solid US Economic News and Easing AI Jitters

The S&P 500 Index ($SPX ) (SPY ) today is up +0.36%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.47%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.40%. March E-mini S&P futures (ESH26...

B : 50.35 (+1.08%)
KNF : 89.38 (+0.90%)
HL : 24.54 (+5.28%)
GPN : 77.85 (-0.12%)
CDE : 26.56 (+8.01%)
ADI : 354.35 (-1.79%)
DDOG : 116.46 (+5.56%)
GLBE : 35.96 (+2.48%)
$IUXX : 25,034.37 (-1.16%)
FIGR : 34.04 (-1.79%)
ZNM26 : 113-180 (+0.18%)
ESH26 : 6,903.00 (-0.25%)
Charles River Laboratories (NYSE:CRL) Beats Q4 CY2025 Sales Expectations

Charles River Laboratories (NYSE:CRL) Beats Q4 CY2025 Sales Expectations

CRL : 175.46 (+4.71%)
Charles River: Q4 Earnings Snapshot

Charles River: Q4 Earnings Snapshot

CRL : 175.46 (+4.71%)
Charles River Laboratories Announces Executive Appointments

Glenn G. Coleman Will Join Charles River as Corporate Executive Vice President and Chief Financial Officer Kerry Dailey Will Join Charles...

CRL : 175.46 (+4.71%)
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance

– Fourth-Quarter Revenue of $994.2 Million and Full-Year Revenue of $4.02 Billion – – Fourth-Quarter GAAP Loss per Share of $(5.62) and Non-GAAP...

CRL : 175.46 (+4.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research...

See More

Key Turning Points

3rd Resistance Point 187.32
2nd Resistance Point 181.40
1st Resistance Point 178.43
Last Price 175.46
1st Support Level 169.54
2nd Support Level 163.62
3rd Support Level 160.65

See More

52-Week High 228.88
Fibonacci 61.8% 176.54
Last Price 175.46
Fibonacci 50% 160.37
Fibonacci 38.2% 144.20
52-Week Low 91.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar